Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics (NMRA) insider filing reports an open-market purchase by affiliated ARCH Venture funds. On 10/27/2025, the reporting persons acquired 1,915,700 shares of common stock at $2.61 per share, reported as indirectly owned.
Following the transaction, indirect beneficial holdings were listed as: 6,046,907 shares by ARCH Venture Fund XII, L.P.; 1,387,228 by ARCH Venture Fund VII, L.P.; 2,321,566 by ARCH Venture Fund VIII Overage, L.P.; 12,205,379 by ARCH Venture Fund X, L.P.; and 11,886,758 by ARCH Venture Fund X Overage, L.P. The filing is a joint submission, and a director relationship is indicated.
Neumora Therapeutics (NMRA): ARCH-affiliated reporting persons disclosed an insider purchase. On 10/27/2025, ARCH Venture Fund XII, L.P. bought 1,915,700 shares of common stock at $2.61 per share (Transaction Code P), reported as indirect ownership.
After the transaction, beneficial holdings reported include: 6,046,907 (ARCH XII); 12,205,379 (ARCH Venture Fund X, L.P.); 11,886,758 (ARCH Venture Fund X Overage, L.P.); 2,321,566 (ARCH Venture Fund VIII Overage, L.P.); and 1,387,228 (ARCH Venture Fund VII, L.P.). The filing was made jointly by multiple ARCH entities and certain individuals, with the relationship indicated as Director.
Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.
This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.
Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.
This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.
Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to 19% as a monotherapy with semaglutide‑like induction, and 26% when combined with high doses of semaglutide. The announcement was made on October 27, 2025.
A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.
Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to 19% as a monotherapy with semaglutide‑like induction, and 26% when combined with high doses of semaglutide. The announcement was made on October 27, 2025.
A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.
Neumora Therapeutics disclosed that K2 HealthVentures Equity Trust LLC and two managing members, Parag Shah and Anup Arora, report beneficial ownership tied to convertible debt that can be converted into Common Stock. Under a loan and security agreement, K2HV Equity has the right to convert up to $10,000,000 of principal into Conversion Shares at the lesser of $0.8774 per share or the lowest effective price in the Issuer's next equity financing; the filers assumed the $0.8774 conversion price.
As a result, the Reporting Persons disclose beneficial ownership of 11,397,310 shares, representing approximately 6.6% of Common Stock on a converted basis. The Schedule shows shared voting and dispositive power over those shares (no sole voting or dispositive power). The reporting address for the filers is provided as 855 Boylston Street, Boston, MA.